Literature DB >> 25669658

Racial/ethnic differences in drug disposition and response: review of recently approved drugs.

A Ramamoorthy1, M A Pacanowski, J Bull, L Zhang.   

Abstract

Race and ethnicity can contribute to interindividual differences in drug exposure and/or response, which may alter risk-benefit in certain populations. Approximately one-fifth of new drugs approved in the past 6 years demonstrated differences in exposure and/or response across racial/ethnic groups, translating to population-specific prescribing recommendations in a few cases. When data from diverse populations were lacking, additional postmarketing studies were recommended. In this review we highlight several cases where race/ethnicity was central to regulatory decision-making.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Mesh:

Substances:

Year:  2015        PMID: 25669658     DOI: 10.1002/cpt.61

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  78 in total

1.  Population Diversity Challenge the External Validity of the European Randomized Controlled Trials Comparing Laparoscopic Gastric Bypass and Sleeve Gastrectomy.

Authors:  Guilherme S Mazzini; Jad Khoraki; Matthew G Browning; Bernardo M Pessoa; Luke G Wolfe; Guilherme M Campos
Journal:  Obes Surg       Date:  2020-03       Impact factor: 4.129

2.  Are the Origins of Precision Medicine Found in the Corpus Hippocraticum?

Authors:  Meropi K Konstantinidou; Makrina Karaglani; Maria Panagopoulou; Aliki Fiska; Ekaterini Chatzaki
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

Review 3.  Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation.

Authors:  Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  NPJ Genom Med       Date:  2020-03-05       Impact factor: 8.617

Review 4.  An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines.

Authors:  Julie Dutil; Zhihua Chen; Alvaro N Monteiro; Jamie K Teer; Steven A Eschrich
Journal:  Cancer Res       Date:  2019-03-20       Impact factor: 12.701

Review 5.  Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.

Authors:  L V Kalman; Jag Agúndez; M Lindqvist Appell; J L Black; G C Bell; S Boukouvala; C Bruckner; E Bruford; K Caudle; S A Coulthard; A K Daly; Al Del Tredici; J T den Dunnen; K Drozda; R E Everts; D Flockhart; R R Freimuth; A Gaedigk; H Hachad; T Hartshorne; M Ingelman-Sundberg; T E Klein; V M Lauschke; D R Maglott; H L McLeod; G A McMillin; U A Meyer; D J Müller; D A Nickerson; W S Oetting; M Pacanowski; V M Pratt; M V Relling; A Roberts; W S Rubinstein; K Sangkuhl; M Schwab; S A Scott; S C Sim; R K Thirumaran; L H Toji; R F Tyndale; Rhn van Schaik; M Whirl-Carrillo; Ktj Yeo; U M Zanger
Journal:  Clin Pharmacol Ther       Date:  2015-11-20       Impact factor: 6.875

6.  Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis.

Authors:  Meghan E McGarry; Susanna A McColley
Journal:  Ann Am Thorac Soc       Date:  2016-10

7.  Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.

Authors:  Haiyan Li; Jingchuan Guo; Glenn F Carlson; Renli Teng
Journal:  Br J Clin Pharmacol       Date:  2016-06-09       Impact factor: 4.335

8.  If We Would Only Ask: How Henrietta Lacks Continues to Teach Us About Perceptions of Research and Genetic Research Among African Americans Today.

Authors:  Bridgette L Jones; Carrie A Vyhlidal; Andrea Bradley-Ewing; Ashley Sherman; Kathy Goggin
Journal:  J Racial Ethn Health Disparities       Date:  2016-09-23

9.  Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.

Authors:  Kenshi Suzuki; Hiroshi Handa; Takaaki Chou; Kenichi Ishizawa; Takatoshi Takubo; Yoichi Kase
Journal:  Int J Hematol       Date:  2016-12-20       Impact factor: 2.490

10.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.